Lymphocyte-predominant Hodgkin's lymphoma

作者：Kriz J^*; Mueller R P; Engert A; Eich H T

来源：Onkologe, 2010, 16(1): 41-+.

DOI：10.1007/s00761-009-1770-5

• Lymphocyte-predominant Hodgkin's lymphoma
• Hodgkin's lymphoma
• Involved-field radiotherapy
• Stage IA
• Rituximab

Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is a rare type of B-cell lymphoma. It is different from the other subtypes of Hodgkin's lymphoma (HL) because of its pathology and clinical course. Differences are also seen in the immunophenotype of the malignant lymphocytic and histiocytic cells (CD20(+), CD15(-), CD30(-)) which differ from the tumor cells in classic HL. Patients are mostly young men with indolent and asymptomatic involvement of peripheral lymph nodes. Despite excellent treatment options in patients with early favorable stages, late relapses are seen over decades after therapy. In stage IA involved-field radiotherapy (IFRT) with 30 Gy is recommended as treatment standard. Recently promising results have been reported by using the chimeric antibody rituximab in the treatment of relapsed patients. Therefore, rituximab was applied in an observational study of the German Hodgkin Study Group (GHSG). Patients in early unfavorable and advanced stages should be treated according to the treatment protocols for classic HL.

• 出版日期2010-1